AdvaMed Statement on President’s Reciprocal Tariff Pause

WASHINGTON — AdvaMed, the medtech association, the world’s largest trade association representing medtech innovators, today released the following statement on the U.S. Centers for Medicare & Medicaid Services’ (CMS) release of its 2026 Home Health Prospective Payment System final rule:

As patient advocates, we’ve witnessed countless stories of hope deferred and lives put on hold while Medicare beneficiaries wait several years for access to breakthrough medical technologies that the FDA has already deemed safe and effective. This unacceptable delay between innovation and access must end. Innovation does not benefit patients without coverage.

WASHINGTON—AdvaMed, the world’s largest trade association representing medtech innovators, today welcomed a letter from U.S. Senators Susan Collins (R-Maine) and Jeanne Shaheen (D-N.H.), co-chairs of the Senate Diabetes Caucus, and U.S. Representatives Diana DeGette (D-Colo.-01) and Gus Bilirakis (R-Fla.-12), co-chairs of the U.S. House Diabetes Caucus, to Centers for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz urging the agency not to finalize a proposal the lawmakers warned could reduce and complicate patient access to continuous glucose monitors (CGMs) and durable insulin pumps.

WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally. 

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.